Clinical trials: Blood Brain Barrier Defect
CNS Lesion, Blood Brain Barrier Defect
P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
The purpose of this study was to determine a safe and effective dose of a new gadolinium-based contrast agent (GBCA) P03277 based on the Contrast to Noise Ratio (CNR) when comparing with gadobenate dimeglumine (MultiHance®) at…
- Trial name
- NCT02633501
- Testing
- P03277, Gadobenate dimeglumine, MRI
- Where
- 28 sites in United States, Belgium and 6 more
- Volunteers
- 312 people
- Sponsor
- Guerbet
Blood Brain Barrier Defect
Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration
The blood-brain barrier (BBB) is an intricate barrier composed of a variety of efflux pumps, a luminal negative charge, a basal lamina and three distinct cell types: brain endothelial cells, pericytes, and astrocyte foot…
- Trial name
- NCT02389738
- Testing
- Regadenoson, Temozolomide, Microdialysis catheter
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
CNS Lesion, Blood Brain Barrier Defect
Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
This trial aimed to evaluate the Efficacy and Safety of gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
- Trial name
- PICTURE (NCT03996447)
- Testing
- gadopiclenol, Gadobutrol 1Mmol/mL Solution for Injection Vial
- Where
- 33 sites in United States, Belgium and 9 more
- Volunteers
- 260 people
- Sponsor
- Guerbet